On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
News
-
-
On March 7, 2019, the U.S. Food & Drug Administration (FDA) released updated draft guidance announcing that it will create special...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 21, 2019, Sandoz Inc. (“Sandoz”) filed suit against Amgen Inc. and Amgen Manufacturing Limited (collectively “Amgen”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, one of three Pfizer IPR petitions filed in April 2017 against Biogen-owned patents claiming methods of treatment...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On November 5, 2018, twenty-nine organizations representing various groups including insurance companies, patient and consumer advocacy...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The August 2018 Update to the PTAB Trial Practice Guide added guidance regarding the Patent Trial and Appeal Board’s (“the Board”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]